Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) Shares Outstanding (Weighted Average) (2016 - 2025)

Apyx Medical's Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $41.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 15.62% year-over-year to $41.1 million; the TTM value through Dec 2025 reached $41.1 million, up 15.62%, while the annual FY2025 figure was $41.1 million, 15.62% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $41.1 million in Q4 2025 per APYX's latest filing, up from $40.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $41.1 million in Q4 2025 to a low of $34.3 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $35.8 million, with a median of $34.6 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 0.01% in 2024, then increased 17.58% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $34.3 million in 2021, then grew by 0.54% to $34.5 million in 2022, then increased by 0.31% to $34.6 million in 2023, then grew by 2.66% to $35.5 million in 2024, then rose by 15.62% to $41.1 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Shares Outstanding (Weighted Average) are $41.1 million (Q4 2025), $40.7 million (Q3 2025), and $40.7 million (Q2 2025).